The safety and efficacy of erlotinib have not been established for individuals with NSCLC whose tumors show other EGFR mutations. Also It's not at all recommended for use together with platinum-primarily based chemotherapy. Label The proposed every day dose of erlotinib for pancreatic cancer is 100 mg taken after day https://lorenzq887cdp7.kylieblog.com/profile